Principal Financial Group Inc. Has $25.65 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Principal Financial Group Inc. lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 25.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 448,087 shares of the biopharmaceutical company’s stock after selling 154,971 shares during the quarter. Principal Financial Group Inc. owned 0.35% of Halozyme Therapeutics worth $25,649,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in shares of Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares during the period. International Assets Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $33,000. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $49,000. Toth Financial Advisory Corp purchased a new position in Halozyme Therapeutics during the third quarter valued at approximately $57,000. Finally, FSC Wealth Advisors LLC purchased a new position in Halozyme Therapeutics during the third quarter valued at approximately $65,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of Halozyme Therapeutics stock opened at $59.61 on Wednesday. The firm has a fifty day simple moving average of $56.53 and a 200-day simple moving average of $53.18. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The stock has a market capitalization of $7.58 billion, a price-to-earnings ratio of 19.74, a PEG ratio of 0.56 and a beta of 1.29.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 70,000 shares of company stock worth $4,042,500. 2.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on HALO. Morgan Stanley boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. TD Cowen boosted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $58.00 to $62.00 in a research report on Monday, October 7th. JMP Securities boosted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Finally, The Goldman Sachs Group boosted their price objective on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.